Back
Edge
StocktwitsEarnings
Official STOCKTWITS Representative
symbol logo$IRWD Q2 '26 Earnings Results & Recap • Reported GAAP EPS of $0.31 up 106.67% YoY • Reported revenue of $113.04M up 32.62% YoY • Ironwood Pharmaceuticals raised its 2026 full-year financial guidance, now expecting U.S. LINZESS net sales of $1.15 to $1.20 billion, total revenue of $460 to $485 million, and adjusted EBITDA greater than $310 million.
1

Price since post

Full Details

Advertisement|Remove ads.